In vitro activity of itraconazole against SARS-CoV-2.
Adenosine
/ analogs & derivatives
Adenosine Monophosphate
/ analogs & derivatives
Alanine
/ analogs & derivatives
Animals
Antiviral Agents
/ pharmacology
Caco-2 Cells
Cell Line, Tumor
Chlorocebus aethiops
Drug Repositioning
Furans
/ pharmacology
Humans
Itraconazole
/ pharmacology
Pyrroles
/ pharmacology
SARS-CoV-2
/ drug effects
Triazines
/ pharmacology
Vero Cells
Virus Replication
/ drug effects
COVID-19 Drug Treatment
17-OH itraconazole
Caco-2 cells
SARS-CoV-2
VeroE6-eGFP cells
in vitro
itraconazole
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
11
02
2021
received:
14
01
2021
accepted:
27
02
2021
pubmed:
6
3
2021
medline:
9
6
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
Although vaccination campaigns are currently being rolled out to prevent coronavirus disease (COVID-19), antivirals will remain an important adjunct to vaccination. Antivirals against coronaviruses do not exist, hence global drug repurposing efforts have been carried out to identify agents that may provide clinical benefit to patients with COVID-19. Itraconazole, an antifungal agent, has been reported to have activity against animal coronaviruses. Using cell-based phenotypic assays, the in vitro antiviral activity of itraconazole and 17-OH itraconazole was assessed against clinical isolates from a German and Belgian patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Itraconazole demonstrated antiviral activity in human Caco-2 cells (EC
Identifiants
pubmed: 33666253
doi: 10.1002/jmv.26917
pmc: PMC8014624
doi:
Substances chimiques
Antiviral Agents
0
Furans
0
Pyrroles
0
Triazines
0
GS-441524
1BQK176DT6
Itraconazole
304NUG5GF4
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Adenosine
K72T3FS567
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4454-4460Subventions
Organisme : Janssen Pharmaceuticals
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Antiviral Res. 2015 Feb;114:1-10
pubmed: 25451075
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Virol Methods. 2005 Oct;129(1):56-63
pubmed: 15961169
Trends Microbiol. 2014 Nov;22(11):642-7
pubmed: 25037114
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
J Med Virol. 2021 Jul;93(7):4454-4460
pubmed: 33666253
mBio. 2018 Jul 24;9(4):
pubmed: 30042202
Cell Rep. 2015 Feb 3;10(4):600-15
pubmed: 25640182
ACS Chem Biol. 2017 Jan 20;12(1):174-182
pubmed: 28103683
Int J Infect Dis. 2020 Aug;97:7-10
pubmed: 32479865
Viruses. 2014 Jul 22;6(7):2826-57
pubmed: 25054883
J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i17-i22
pubmed: 16120630
Cancer Cell. 2010 Apr 13;17(4):388-99
pubmed: 20385363
Annu Rev Virol. 2014 Nov;1(1):453-73
pubmed: 26958730
Lancet. 2003 Jul 26;362(9380):293-4
pubmed: 12892961
Cell Host Microbe. 2013 Apr 17;13(4):452-64
pubmed: 23601107
Drug Metab Dispos. 2012 Mar;40(3):426-35
pubmed: 22106171
Antiviral Res. 2018 Aug;156:55-63
pubmed: 29807040
Vet Res. 2019 Jan 18;50(1):5
pubmed: 30658691
Br J Pharmacol. 2021 Jun;178(11):2339-2350
pubmed: 33825201
Emerg Microbes Infect. 2019;8(1):80-93
pubmed: 30866762
Sci Rep. 2016 Mar 15;6:23110
pubmed: 26976677
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Biochim Biophys Acta. 2007 Mar;1770(3):467-77
pubmed: 16963187
Antimicrob Agents Chemother. 1988 Jan;32(1):1-8
pubmed: 2831809
Cell. 2015 Dec 17;163(7):1716-29
pubmed: 26686653
Antiviral Res. 2017 Sep;145:96-102
pubmed: 28780424
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):89-94
pubmed: 27994139
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
PLoS One. 2013;8(2):e56265
pubmed: 23441171
Med Mycol. 2005 May;43 Suppl 1:S313-9
pubmed: 16110826
Pathogens. 2019 Dec 16;8(4):
pubmed: 31888266